Loading...

ARVN ARVINAS INC Expansion Plans 8-K Filing

RVNS

RVN

ARVINAS INC

(ARVN)

2025 8-K

Positive Clinical Data

Financial Results Report

Management Changes

Preclinical Data Release

Financial Update

Data Announcement

Positive Trial Results

Workforce Reduction

Financial Statements

Product Expansion

New Product Launches

Product Expansion

Management Changes

Product Expansion

Clinical Trial Results

Clinical Trial Results

Financial Results

Lease Termination

Clinical Trial Update

Lease Amendment

Lease Amendments

Clinical Trial Update

Clinical Trial Update

Financial Results

Lease Termination

Financial Results Announcement

Appointment of CFO

Agreement with Yale University

Appointment of Officers

Annual Meeting of Stockholders

Transaction with Novartis

Clinical Trial Update

Earnings Reports

Entry into Material Definit...

Appointment of Chief Medica...

Financial Results Announcement

Departure of CFO and Appoin...

Interim Data Announcement

Private Placement

Financial Results Announcement

Clinical Trial Data Announc...

Financial Results Announcement

Amendment of Bylaws

Interim Data Announcement

Earnings Reports

Regulation FD Disclosure

Earnings Reports

Guidance Update

External Links:

On October 5, 2025, Arvinas, Inc. announced promising Phase 1 clinical trial results for its drug ARV-102, showing over 90% LRRK2 protein reduction in blood and safe tolerability at doses up to 200 mg. The company plans further studies in patients with Parkinson’s disease and progressive supranuclear palsy.

AI Assistant

ARVINAS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.